Loading
A phase 1/2 trial of Trastuzumab deruxtecan, Durvalumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by AstraZeneca, active and no longer recruiting.
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04538742 by AstraZeneca, with 245 participants enrolled, started 2020-12-28 and due to reach its primary completion in 2025-01-31. Interventions recorded: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab and Tucatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Tucatinib, Pertuzumab, Daiichi Sankyo, HER2-positive breast cancer and the tag pipeline.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Durvalumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab deruxtecan, Durvalumab, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pertuzumab, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/